Pfizer has acquired Metsera for $4.9 billion upfront with potential payments raising the deal to $7.3 billion, regaining a foothold in the competitive obesity drug space after recent internal setbacks. Metsera, a New York-based biotech with a pipeline of injectable and oral weight loss therapies, offers candidates designed for improved dosing convenience and tolerability. Data from phase 2 trials are anticipated in 2026, underpinning investor optimism. This acquisition bolsters Pfizer’s metabolic disorder portfolio and occurs amid significant marketing efforts to revitalize its obesity drug pipeline.